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Abstract
Background: Warfarin related nephropathy is one of the potential complications of warfarin therapy. Despite the
well described histological entity, the clinical course and approach to warfarin related nephropathy in patients
requiring life-long anticoagulation is however not well described in the literature.
Case presentation: We report the clinical course of a 56 years old Chinese lady who presented with over anti-
coagulation and acute kidney injury while on warfarin therapy for permanent atrial fibrillation and mechanical valve
replacement. Renal biopsy was performed as the acute kidney injury was persistent despite normalization of the
International Normalized Ratio and the diagnosis of warfarin related nephropathy was made. Temporary interruption of
anti-coagulation, in combination with oral N-acetylcysteine resulted in subsequent stabilization of renal function.
Conclusion: The diagnosis of warfarin induced nephropathy should be considered in patients presenting with
unexplained acute kidney injury and over anti-coagulation. Awareness of this clinical entity is important for clinician
managing anti-coagulation therapy and renal function should be monitored regularly in patients who are on warfarin
therapy.
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Background
The potential deleterious effect of warfarin in patients
with chronic kidney disease (CKD) was first observed in
the 1970s. Warfarin, when given in anticoagulant dose
as part of the “Melbourne cocktail” for the treatment of
IgA nephropathy, was noted to result in an increase in
urinary red blood cell counts [1]. Subsequently in 2009,
Brodsky et al. reported a case series of 9 CKD patients
with biopsy proven acute kidney injury during warfarin
therapy [2]. The documented histological finding of
acute tubular injury in the presence of glomerular
hemorrhage became the hallmark feature of warfarin re-
lated nephropathy (WRN). An animal model validating
WRN was subsequently reported [3] and retrospective
analysis of databases of patients receiving warfarin ther-
apy revealed that WRN could occur in patients without
CKD and was associated with accelerated progression of
CKD when above therapeutic range [4–6].
Despite the well described clinical entity, the clinical
course of WRN remains unclear. In the original case
series reported by Brodsky, four patients remained dialy-
sis dependent and many did not recover despite
normalization of the international normalized ratio
(INR). Moreover, the outcome of WRN in patients
where anti-coagulation should not be stopped perman-
ently, such as in patients with mechanical heart valve, is
unclear. We report the clinical course of a patient with
WRN where anti-coagulation could not be stopped
permanently.
Case presentation
A 56 years old diabetic chinese lady with atrial fibrilla-
tion and mechanical mitral valve replacement (Bileaflet
tilting disc valve, St Jude) was found to be over anti-
coagulated [international normalized ratio (INR) of 4.95]
during a routine follow up. She had been on warfarin
therapy since 2001 for permanent atrial fibrillation and
remained on anticoagulation after her valve replace-
ment surgery for severe mitral stenosis secondary to
rheumatic heart disease in 2008. Her medications
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included warfarin 3 mg OD, digoxin 250 mcg OD,
bisoprolol 1.25 mg OD, fenofibrate 300 mg OD, fur-
osemide 20 mg OD, potassium chloride 600 mg OD,
glipizide 2.5 mg BiD and metformin 850 mg BiD.
There were no recent changes in her medication and
diet. On physical examination, she was well with no
overt signs of bleeding. Her blood pressure was 130/
70 mm Hg with a heart rate of 60 beats per minute.
Fundoscopy did not reveal the presence of any hem-
orrhages or diabetic retinopathy.
The serum creatinine was noted to be elevated at
317 μmol/L, a five-fold increase from her last mea-
sured serum creatinine of 72 μmol/L 6 months ago.
The provisional diagnosis was acute kidney injury
(AKI) in the background of over anti-coagulation and
diabetes mellitus. Further investigations were per-
formed to elucidate the cause of her acute kidney in-
jury. Urine microscopy revealed microscopic
hematuria (Red blood cell 675/UL). Ultrasonography
and computed tomography showed normal size kid-
neys with no evidence of urinary calculi or obstruc-
tion respectively. Autoimmune markers including
anti-neutrophil cytoplasmic antibody, antinuclear anti-
body, anti-double stranded DNA and anti-glomerular
basement membrane antibody were negative and
there was no hypocomplementemia. Her urine culture
was negative and 24-hour urine protein was 0.35 g/
day.
Warfarin was initially suspended to restore a thera-
peutic INR level. Decision was subsequently made for
a renal biopsy 12 days after admission due to persist-
ent AKI. Histology showed focal segmental and global
glomerulosclerosis with mesangial hypercellularity but
no crescents. The interstitium was edematous with
presence of acute tubular necrosis. Specifically, a
number of tubules demonstrated red cell casts, which
were consistent with warfarin related nephropathy
(Fig. 1). Immunofluorescence was not performed due
to inadequate tissue sample. Electron microscopy, car-
ried out on appropriately reprocessed material derived
from the paraffin block, showed several electron
dense deposits in the mesangial and paramesangial
zones, suggestive of underlying IgA nephropathy. All
anticoagulation therapy was interrupted for 5 days
post renal biopsy due to the development of peri-
nephric hematoma. Oral acetylcysteine 1.2 g BiD,
followed by oral prednisolone 30 mg OD was started
when the serum creatinine increased to 428 μmol/L.
The serum creatinine improved to 274 μmol/L with
the above interventions. The patient was bridged with
low molecular weight heparin before being restarted
back on warfarin, with a target INR of 2–2.5. The
serum creatinine and INR 3 months post discharge
were 274 μmol/L and 2.1 respectively. The INR and
creatinine trends are as summarized in Fig. 2.
Discussion
As illustrated in our patient, WRN is an important differen-
tial diagnosis in the evaluation of unexplained AKI in pa-
tients on warfarin therapy, especially in the presence of
Fig. 1 a. Masson trichrome-silver stain shows a glomerulus with a small segment of sclerosis (arrow) that is adherent to the Bowman’s capsule. A
few tubules around the glomerulus show luminal red cell casts. b. Low magnification of several tubules containing luminal red cell casts. c. High
magnification of a glomerulus demonstrating segmental mesangial matrix expansion and increased mesangial cells. d. Electron micrograph shows
paramesangial electron dense deposits
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over anti-coagulation and microscopic hematuria. Although
the renal biopsy showed background Ig A nephropathy, the
patient had normal renal function prior to admission. The
AKI was probably precipitated by over anti-coagulation,
which was consistent with what was reported in the
literature.
The management of WRN in patients where anti-
coagulation should not be stopped permanently poses a
management dilemma. The lifetime risk of mechanical
valve thrombosis following permanent cessation of warfarin
is exceedingly high and potentially life-threating [7]. As of
now, the only novel oral anticoagulant (NOAC) drug that
has been studied in patients with mechanical valves is dabi-
gatran. In the RE-ALIGN study, dabigatran, as compared
with warfarin, was associated with excess thromboembolic
and bleeding events and as such is currently not indicated
for use in patients with mechanical valve replacements [8].
Moreover, WRN has also been reported with dabigatran in
animal models [9]. Intuitively, temporary interruption of
anti-coagulation may ameliorate glomerular bleeding and
result in stabilization of the renal function; however, the
risks of thromboembolic events need to be taken into con-
sideration. Extrapolating experience from management of
intracranial hemorrhage in patients with mechanical heart
valve, the incidence of thromboembolic events without
anticoagulation in patients with mechanical heart valve was
estimated to be 0.06 % per day [10]. Indeed, the European
Stroke Initiative recommended that patients with very high
risk for thromboembolic events should be restarted on war-
farin after 10 to 14 days after intra-cranial hemorrhage [11].
In our patient, anticoagulation was interrupted for 5 days
in view of post biopsy hematoma and this might have lim-
ited the extent of glomerular bleeding and renal
dysfunction.
While glomerular hematuria is the inciting event
in WRN, the dominant mechanism of AKI was sec-
ondary to tubular obstruction by red blood cell casts
and the increased oxidative stress in the kidney. N-
acetylcysteine is a well-characterized antioxidant,
which has been used for many years in experimental
research. Specifically, it has been shown to prevent
increases in creatinine in a dose-dependent manner
in animal models of warfarin induced AKI [12] and
was used without any adverse reaction in our pa-
tient. We postulated that temporary interruption of
anti-coagulation in conjunction with N-acetylcystine
might have resulted in the stabilization of renal
function that was observed in our patient.
The anti-inflammatory effect of steroids may also be use-
ful in mitigating the onset of interstitial fibrosis as a
Fig. 2 INR and serum creatinine trend of the patient
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consequence of WRN. Specifically in our patient, the bene-
ficial effect may be secondary to its impact on the concur-
rent IgA nephropathy and interstitial edema. While early
steroid administration was reported to accelerate recovery
of AKI after gross haematuria in IgA nephropathy [13], the
use of prednisolone in WRN is not strongly supported in
experimental models and is limited to a single prior case re-
port [14]. Nevertheless, based on our anecdotal evidence,
the use of steroids in WRN requires further validation.
Conclusion
In conclusion, renal function should be monitored in pa-
tients on anticoagulation therapy and the diagnosis of
WRN, especially in the presence of over anticoagulation,
should be considered in patient with unexplained AKI.
Temporary interruption of anticoagulation in combination
with N-acetylcystine may result in stabilization of the renal
function. Low dose corticosteroids may be added as it can
potentially suppress the inflammatory response following
glomerular hemorrhage and tubular obstruction in the
kidney.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying im-
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